Download PDF
Exp Clin Endocrinol Diabetes 1992; 99(2): 73-76
DOI: 10.1055/s-0029-1211138
Original

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Somatomedin-C/IGF-I, Insulin and Prolactin Levels in Ullrich-Turner's Syndrome

P. Amendt, V. Hesse, W. Rohde
  • Childrens Hospital (Director: Prof. Dr. sc. med. E. L. Granel) and Institute for Experimental Endocrinology (Director: Prof. Dr. sc. med. Dr. h.c. G. Dörner), Humboldt-University, School of Medicine (Charité), Berlin; Childrens Hospital Lindenhof (Director: Prof. Dr. sc. med. V. Hesse), Berlin/Germany
Further Information

Publication History

1991

Publication Date:
15 July 2009 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

To clarify the pathogenesis of growth retardation in patients with Ullrich-Turner's syndrome (TS) we have investigated basal SmC/IGF-I, insulin and prolactin concentrations. Compared with 56 age matched healthy controls basal SmC/ IGF-I concentration in 51 patients with TS older than 9—11 years was significantly lower (age group 13—14 years; TS 273 ± 47 and controls 479 ± 114 ng/ml). Mean basal prolactin level in 43 patients with TS (406 ±211 µU/ml) was significantly higher (p < 0.01) than in 192 female controls (age 3—11 years; 264 ±176 µU/ml). Basal insulin concentration in 28 TS patients in comparison to 20 healthy children of a control group was significant higher (TS 18 ± 8 µU/ml; controls 9 ± 4 µU/ ml; p < 0.01). It seems that neither insulin nor prolactin are relevant stimulators of SmC/IGF-I in man, especially in patients with gonadal dysgenesis. Considering these results we speculate that despite higher prolactin and higher insulin levels in TS, the lower SmC/IGF-I concentrations may be predominantly related to the abnormal sex steroid secretion.

Key words

Turner's syndrome - Growth factors - Insulin secretion - Prolactin secretion

      >